Overlap of Genetic Loci for Central Serous Chorioretinopathy With Age-Related Macular Degeneration
Authors: Rämö Joel T. , Abner Erik , van Dijk Elon H. C. , Wang Xin , Brinks Joost , Nikopensius Tiit , Nõukas Margit , Marjonen Heidi , Silander Kaisa , Jukarainen Sakari , Kiiskinen Tuomo , Choi Seung Hoan , Kajanne Risto , Mehtonen Juha , Palta Priit , Lubitz Steven A. , Kaarniranta Kai , Sobrin Lucia , Kurki Mitja , Yzer Suzanne , Ellinor Patrick T. , Esko Tõnu , Daly Mark J. , den Hollander Anneke I. , Palotie Aarno , Turunen Joni A. , Boon Camiel J. F. , Rossin Elizabeth J. ,   FinnGen Study,   Estonian Biobank Research Team
Published: April 2023

ImportanceCentral serous chorioretinopathy (CSC) is a serous maculopathy of unknown etiology. Two of 3 previously reported CSC genetic risk loci are also associated with AMD. Improved understanding of CSC genetics may broaden our understanding of this genetic overlap and unveil mechanisms in both diseases.ObjectiveTo identify novel genetic risk factors for CSC and compare genetic risk factors for CSC and AMD.Design, Setting, and ParticipantsUsing International Classification of Diseases, Ninth (ICD-9) and Tenth (ICD-10) Revision code-based inclusion and exclusion criteria, patients with CSC and controls were identified in both the FinnGen study and the Estonian Biobank (EstBB). Also included in a meta-analysis were previously reported patients with chronic CSC and controls. Data were analyzed from March 1 to September 31, 2022.Main Outcomes and MeasuresGenome-wide association studies (GWASs) were performed in the biobank-based cohorts followed by a meta-analysis of all cohorts. The expression of genes prioritized by the polygenic priority score and nearest-gene methods were assessed in cultured choroidal endothelial cells and public ocular single-cell RNA sequencing data sets. The predictive utility of polygenic scores (PGSs) for CSC and AMD were evaluated in the FinnGen study.ResultsA total of 1176 patients with CSC and 526 787 controls (312 162 female [59.3%]) were included in this analysis: 552 patients with CSC and 343 461 controls were identified in the FinnGen study, 103 patients with CSC and 178 573 controls were identified in the EstBB, and 521 patients with chronic CSC and 3577 controls were included in a meta-analysis. Two previously reported CSC risk loci were replicated (near CFH and GATA5) and 3 novel loci were identified (near CD34/46, NOTCH4, and PREX1). The CFH and NOTCH4 loci were associated with AMD but in the opposite direction. Prioritized genes showed increased expression in cultured choroidal endothelial cells compared with other genes in the loci (median [IQR] of log 2 [counts per million], 7.3 [0.6] vs 4.7 [3.7]; P = .004) and were differentially expressed in choroidal vascular endothelial cells in single-cell RNA sequencing data (mean [SD] fold change, 2.05 [0.38] compared with other cell types; P &amp;lt; 7.1 × 10−20). A PGS for AMD was predictive of reduced CSC risk (odds ratio, 0.76; 95% CI, 0.70-0.83 per +1 SD in AMD-PGS; P = 7.4 × 10−10). This association may have been mediated by loci containing complement genes.Conclusions and RelevanceIn this 3-cohort genetic association study, 5 genetic risk loci for CSC were identified, highlighting a likely role for genes involved in choroidal vascular function and complement regulation. Results suggest that polygenic AMD risk was associated with reduced risk of CSC and that this genetic overlap was largely due to loci containing complement genes.